ArticleScientific reports2024
Effective protection of biological tissues from severe blunt force injury by engineered nanoscale liquid flow.
Article in Scientific reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Blunt force trauma (BFT), the injury of the body by forceful impacts such as falls, motor vehicle crashes and collisions, causes damage to bio-organs that can lead to life-threatening situations. To address the unmet need of bioprotection materials for BFT, we developed a novel, liquid nanofoam (LN)-based system. The LN system employs a unique mechanism of energy absorption, i.e. the external force-aided, nanoscale liquid flow. Under mechanical loading, the LN system effectively protected human cells from force-induced deformation and cell death. In addition to effective mitigation of the upregulation of stress and inflammatory genes, LN prevented blunt-force-induced damage of multiple vital organs including liver, kidney, heart, and lungs. To our knowledge, this is the first material of its kind that is biocompatible and capable of effectively protecting biotissues from BFT on molecular, cellular and tissue levels.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.